These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23839261)

  • 1. Improving access to medicines: empowering patients in the quest to improve treatment for rare lethal diseases.
    Halpin L; Savulescu J; Talbot K; Turner M; Talman P
    J Med Ethics; 2015 Dec; 41(12):987-9. PubMed ID: 23839261
    [No Abstract]   [Full Text] [Related]  

  • 2. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
    Finkelstein PE
    AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587
    [No Abstract]   [Full Text] [Related]  

  • 3. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.
    Kim S; Kim JK; Son MJ; Kim D; Song B; Son I; Kang HW; Lee J; Kim S
    Trials; 2018 Apr; 19(1):225. PubMed ID: 29653550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis.
    Bensimon G; Lacomblez L; Delumeau JC; Bejuit R; Truffinet P; Meininger V;
    J Neurol; 2002 May; 249(5):609-15. PubMed ID: 12021952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verapamil and riluzole cocktail liposomes overcome pharmacoresistance by inhibiting P-glycoprotein in brain endothelial and astrocyte cells: A potent approach to treat amyotrophic lateral sclerosis.
    Yang T; Ferrill L; Gallant L; McGillicuddy S; Fernandes T; Schields N; Bai S
    Eur J Pharm Sci; 2018 Jul; 120():30-39. PubMed ID: 29704642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials.
    Barp A; Gerardi F; Lizio A; Sansone VA; Lunetta C
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):145-164. PubMed ID: 32456491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of amyotrophic lateral sclerosis with riluzole.
    Neatherlin JS
    J Neurosci Nurs; 1998 Aug; 30(4):257-60. PubMed ID: 9791781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000.
    Traynor BJ; Alexander M; Corr B; Frost E; Hardiman O
    J Neurol; 2003 Apr; 250(4):473-9. PubMed ID: 12700914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riluzole prescribing, uptake and treatment discontinuation in people with amyotrophic lateral sclerosis in Scotland.
    Jayaprakash K; Glasmacher SA; Pang B; Beswick E; Mehta AR; Dakin R; Newton J; Chandran S; Pal S;
    J Neurol; 2020 Aug; 267(8):2459-2461. PubMed ID: 32447548
    [No Abstract]   [Full Text] [Related]  

  • 11. The alchemy of informed consent.
    Hull RT
    J Clin Ethics; 2002; 13(1):63-6. PubMed ID: 12235685
    [No Abstract]   [Full Text] [Related]  

  • 12. The practice of autonomy and the practice of bioethics.
    Schneider CE
    J Clin Ethics; 2002; 13(1):72-7. PubMed ID: 12235687
    [No Abstract]   [Full Text] [Related]  

  • 13. Disputing the ethics of research: the challenge from bioethics and patient activism to the interpretation of the Declaration of Helsinki in clinical trials.
    Woods S; McCormack P
    Bioethics; 2013 Jun; 27(5):243-50. PubMed ID: 22296646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Orphan Drug Act Revisited.
    Thomas S; Caplan A
    JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155
    [No Abstract]   [Full Text] [Related]  

  • 16. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis.
    Gurney ME; Fleck TJ; Himes CS; Hall ED
    Neurology; 1998 Jan; 50(1):62-6. PubMed ID: 9443458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ethics of the physician-patient relationship.
    Lie RK
    Ethical Perspect; 1997 Dec; 4(4):263-70. PubMed ID: 15712433
    [No Abstract]   [Full Text] [Related]  

  • 18. Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics.
    Breiner A; Zinman L; Bourque PR
    CMAJ; 2020 Mar; 192(12):E319-E320. PubMed ID: 32392516
    [No Abstract]   [Full Text] [Related]  

  • 19. Amyotrophic lateral sclerosis, excitotoxicity and riluzole.
    Obrenovitch TP
    Trends Pharmacol Sci; 1998 Jan; 19(1):9-11. PubMed ID: 9509893
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cotreatment of amyotrophic lateral sclerosis patients].
    Iwasaki Y; Ikeda K
    Rinsho Shinkeigaku; 1999 Dec; 39(12):1253-5. PubMed ID: 10791091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.